WIX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Wix.com is not a good buy right now for a Beginner long-term investor with $50,000-$100,000 to deploy. The stock has bounced on the day, but the broader setup is still weak: bearish moving averages, negative MACD, soft quarterly results, and multiple analyst price-target cuts after earnings. While there are long-term AI/product catalysts, the current risk-reward is still mixed, so I would not call this a clear buy today.
WIX is trading at 55, slightly above its pivot of 55.051, with resistance at 57.443 and support at 52.66. The trend remains bearish overall because SMA_200 > SMA_20 > SMA_5, which shows the stock is below a longer-term downtrend structure. MACD histogram is -0.5 and still negative, though contracting, suggesting downside momentum is easing but not yet reversed. RSI_6 is 42.05, which is neutral-to-weak and not yet oversold. The recent 4.65% regular-session gain and 1.98% pre-market gain show short-term recovery, but the trend confirmation is still lacking.
["Base44 continues to show strong ARR growth and is viewed by analysts as an important AI-related growth driver.", "Management is pushing AI-related product development, including a proprietary LLM and broader AI positioning.", "Some analysts still maintain Buy/Outperform ratings despite lowering price targets, showing the long-term thesis is not broken."]
["Wix reported Q1 2026 earnings and revenue below expectations, which triggered a sharp stock drop.", "There is an ongoing securities fraud investigation following the disappointing results and share decline.", "Analysts broadly cut price targets, reflecting weaker near-term fundamentals and margin pressure.", "Core Wix and Partner business trends are slowing, and free cash flow margin guidance has weakened.", "Foreign-exchange pressure from USD/Shekel is a headwind in Q2 and expected to worsen in the second half."]
Latest quarter: Q1 2026. The quarter was weaker than expected, with revenue and earnings below estimates. Analysts highlighted lower free cash flow margins, softer Partner revenue growth, and pressure from currency effects. On the positive side, Base44 growth was strong and core margins were still described by some analysts as stable, but overall the latest quarter showed slowing core momentum and weaker profitability outlook.
Analyst sentiment has turned more cautious recently, with multiple firms cutting price targets after Q1. BofA lowered its target to $77 from $95 but kept Buy; Morgan Stanley cut to $112 from $125 and stayed Overweight; Oppenheimer cut to $85 from $115 and stayed Outperform; B. Riley cut to $150 from $180 and stayed Buy; Scotiabank cut to $110 from $135 and stayed Outperform; Needham cut to $80 from $115 and stayed Buy; Cantor cut to $70 from $110 and stayed Overweight; UBS cut to $68 from $96 and stayed Neutral; Wells Fargo downgraded to Equal Weight with a $54 target. Wall Street is split, but the overall tone is bearish-to-neutral on the near term, with pros citing long-term AI and Base44 upside, and cons focused on slowing core growth, margin compression, and weaker FCF.
